Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of<sup>18</sup>F-Fluoride Metabolic Flux Than with Measurement of<sup>18</sup>F-Fluoride PET/CT SUV?

Gurdip Azad, Musib Siddique, Benjamin Taylor, Adrian J. Green, Jim O’Doherty, Joanna Gariani, Glen M. Blake, Janine Mansi, Vicky Goh, Gary Cook

Journal of Nuclear Medicine · 2018 · 26 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

Our purpose was to establish whether noninvasive measurement of changes in <sup>18</sup>F-fluoride metabolic flux to bone mineral (K<sub>i</sub>) by PET/CT can provide incremental value in response assessment of bone metastases in breast cancer compared with SUV<sub>max</sub> and SUV<sub>mean</sub>. <b>Methods:</b> Twelve breast cancer patients starting endocrine treatment for de novo or progressive bone metastases were included. Static <sup>18</sup>F-fluoride PET/CT scans were acquired 60 min after injection, before and 8 wk after commencing treatment. Venous blood samples were taken at 55 and 85 min after injection to measure plasma <sup>18</sup>F-fluoride activity concentrations, and K<sub>i</sub> in individual bone metastases was calculated using a previously validated method. Percentage changes in K<sub>i</sub>, SUV<sub>max</sub>, and SUV<sub>mean</sub> were calculated from the same index lesions (≤5 lesions) from each patient. Clinical response up to 24 wk, assessed in consensus by 2 experienced oncologists masked to PET imaging findings, was used as a reference standard. <b>Results:</b> Of the 4 patients with clinically progressive disease (PD), mean K<sub>i</sub> significantly increased (&gt;25%) in all, SUV<sub>max</sub> in 3, and SUV<sub>mean</sub> in 2. Of the 8 non-PD patients, K<sub>i</sub> decreased or remained stable in 7, SUV<sub>max</sub> in 5, and SUV<sub>mean</sub> in 6. A significant mean percentage increase from baseline for K<sub>i</sub>, compared with SUV<sub>max</sub> and SUV<sub>mean</sub>, occurred in the 4 patients with PD (89.7% vs. 41.8% and 43.5%, respectively; <i>P</i> &lt; 0.001). <b>Conclusion:</b> After 8 wk of endocrine treatment for bone-predominant metastatic breast cancer, K<sub>i</sub> more reliably differentiated PD from non-PD than did SUV<sub>max</sub> and SUV<sub>mean</sub>, probably because measurement of SUV underestimates fluoride clearance by not considering changes in input function.

References

33